Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (43)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Westphal, J. F.
Right arrow Articles by Brogard, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Westphal, J. F.
Right arrow Articles by Brogard, J. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1994) 33, 387-401
© 1994 The British Society for Antimicrobial Chemotherapy

review-article

Hepatic side-effects of antibiotics

J. F. Westphala, D. Vetterb and J. M. Brogarda

aInternal Medicine Service CHRU, 67091 Strasbourg Cedex, France bHepatogastroenterology Service, Medical B Clinic, 1 place de I'Hôpital CHRU, 67091 Strasbourg Cedex, France

Received 22 March 1993; accepted 26 July 1993

Although the liver is particularly exposed to drugs and their metabolites, hepatic side-effects of antibiotics are far less frequent than other adverse effects such as gastrointestinal disorders or cutaneous reactions. However, the potential severity of hepatic side-effects for some drugs is stressed. Antibiotic related liver injuries cover most of the clinical and pathological expressions of hepatic dysfunction, including cytotoxic hepatitis (isoniazid), intrahepatic cholestasis (macrolides, penicillins, clavulanic acid), mixed hepatitis (sulphonamides), chronic active hepatitis (nitrofurantoin), or microvesicular steatosis (tetracycline). In most cases, toxicity is idiosyncratic, reactions occurring only in some susceptible individuals. The mechanisms underlying toxicity may be primarily metabolite-dependent (isoniazid), hypersensitivity-mediated (ßlactams), or result from both processes (sulphonamides, erythromycin derivatives). In some cases, the liver is not the primary target organ for toxicity but appears to mediate the clinical expression of some adverse effects induced by antibiotics. The most significant example of this is hypoprothrombinaemia due to the inhibition of hepatic {gamma}-carboxylation of vitamin K-dependent clotting factors by sulphydryl group-containing cephalosporins. Inhibition of bilirubin conjugation or transport by rifampicin or fusidic acid may also be viewed as hepatic side-effects of antibiotics. Ascertaining the casual relationship of a given drug to an hepatic adverse effect may prove particularly difficult, because of the potential contribution of host status and concurrent medications. Diagnosis is based mainly on circumstantial evidence, i.e. the temporal relationship between drug administration (or withdrawal) and the time-course of liver dysfunction. Improving morbidity related to drug hepatotoxicity relies on a free flow of information between manufacturers and practitioners in order to optimize detection of potentially serious liver damage, and advances in pharmacogenetics toward a better identification of those at particular risk for developing drug-related liver toxicity.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ChestHome page
Y. Suzuki, S. Miwa, M. Shirai, H. Ohba, M. Murakami, K. Fujita, T. Suda, H. Nakamura, H. Hayakawa, and K. Chida
Drug Lymphocyte Stimulation Test in the Diagnosis of Adverse Reactions to Antituberculosis Drugs
Chest, November 1, 2008; 134(5): 1027 - 1032.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
H.-Q. Yin, M. Kim, J.-H. Kim, G. Kong, M.-O. Lee, K.-S. Kang, B.-I. Yoon, H.-L. Kim, and B.-H. Lee
Hepatic Gene Expression Profiling and Lipid Homeostasis in Mice Exposed to Steatogenic Drug, Tetracycline
Toxicol. Sci., November 1, 2006; 94(1): 206 - 216.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S. Koklu, A. S Koksal, M. Asil, H. Kiyici, S. Coban, and M. Arhan
Probable Sulbactam/Ampicillin-Associated Prolonged Cholestasis
Ann. Pharmacother., December 1, 2004; 38(12): 2055 - 2058.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S. Koklu, O. Yuksel, O. F. Yolcu, M. Arhan, and E. Altiparmak
Cholestatic attack due to ampicillin and cross-reactivity to cefuroxime
Ann. Pharmacother., September 1, 2004; 38(9): 1539 - 1540.
[Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S. Koklu, O. Yuksel, L. Filik, O. Uskudar, K. Altundag, and E. Altiparmak
Recurrent Cholestasis Due to Ampicillin
Ann. Pharmacother., March 1, 2003; 37(3): 395 - 397.
[Abstract] [Full Text] [PDF]

Home page
 Hum Exp ToxicolHome page
L. Nicod, C. Viollon, A. Regnier, A. Jacqueson, and L. Richert
Rifampicin and isoniazid increase acetaminophen and isoniazid cytotoxicity in human HepG2 hepatoma cells
Human and Experimental Toxicology, January 1, 1997; 16(1): 28 - 34.
[Abstract] [PDF]

Home page
 NEJMHome page
W. M. Lee
Drug-Induced Hepatotoxicity
N. Engl. J. Med., October 26, 1995; 333(17): 1118 - 1127.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.